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Background: We report a case of childhood onset, generalized dystonia due to slowly progressive bilateral striatal
necrosis associated with anti-N-methyl-D-aspartate receptor (NMDAR) antibodies. This clinical phenotype has not
been previously associated with NMDA receptor autoimmunity.
Case presentation: An eighteen year old man presented with a history of childhood-onset, progressive
generalized dystonia. Clinical examination revealed a pure generalized dystonia with no cognitive or other
neurological findings. Magnetic resonance imaging showed bilateral high T2 signal striatal lesions, which were
slowly progressive over a period of nine years. New parts of the lesion showed restricted water diffusion suggesting
cytotoxic oedema. Positron emission tomography of the brain showed frontal hypermetabolism and cerebellar
hypometabolism. Antibodies against the NR1 subunit of the NMDA receptor were detected in the patient’s serum
and cerebrospinal fluid. There was no neoplasia or preceding infection or vaccination.
Conclusion: This is the first report of chronic progressive bilateral striatal necrosis associated with anti-NMDAR
antibodies. Our findings expand the clinical spectrum of disease associated with anti-NMDAR antibodies and
suggest that these should be included in the work-up of dystonia with striatal necrosis.
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Background including choreoathetosis, myoclonus and dystonia [4-7]
Generalized dystonia due to bilateral striatal necrosis
(BSN) has a heterogeneous etiology including hereditary,
toxic, infectious and immune mediated disorders. Immune
mediated BSN is a rare clinical entity [1] which has been
associated with a variety of infectious agents including
streptococci [2] and mycoplasma [3]. An infectious or
parainfectious pathomechanism has been proposed, but
the pathogenesis of these disorders remains unclear.
Basal ganglia involvement occurs commonly in the
encephalitis associated with anti-N-methyl-D-aspartate
receptor (NMDAR) antibodies. This acute or subacute
illness can manifest psychiatric and neurological symp-
toms including epileptic seizures, autonomic instability,
hypoventilation and decreased levels of consciousness.
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reproduction in any medium, provided the orduring the course of the illness, but chronic progressive
dystonia has not been reported. While magnetic resonance
imaging (MRI) of the brain may show T2 hyperintense
lesions in various parts of the brain including the basal
ganglia, progressive BSN has never previously been
described [5-8]. Diagnosis is confirmed by detecting
autoantibodies against the NR1 subunit of NMDA-type
glutamate receptors in serum or CSF [5,7]. NMDAR
encephalitis may be associated with neoplasms, usually
teratomas of the ovaries or testes, but may also be
postinfectious or idiopathic. Treatment consists of
tumor resection and administration of immunosuppressant
therapy usually in the form of intravenous immunoglobulin
(IVIg) or plasma exchange with substantial recovery in
about 75% of the cases [6,8].
We report a case of childhood onset, pure generalized
dystonia due to slowly progressive BSN, associated with
anti-NMDAR antibodies. Our patient’s presentation,
course and clinical features have not been previously
associated with anti-NMDAR autoimmunity.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Axial T2-weighted MRI showing progression of the
striatal lesions at the ages of nine (A), ten (B), fourteen (C),
seventeen (D1&D2) and eighteen (E) years.
Figure 2 Axial diffusion weighted scans (b1000) and
corresponding ADC maps showing the evolution of diffusion
changes in the left caudate head at seventeen (A&B) and
eighteen (C&D) years of age. The newest parts of the lesion
(arrow) show low ADC consistent with restricted water diffusion.
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The patient, now an eighteen year old man, was born
after normal pregnancy and delivery and had normal
early psychomotor development. From the age of three
years he experienced episodic migraine-like headache,
which resolved spontaneously at the age of sixteen. From
the age of nine he noticed slowly progressive difficulties
with handwriting due to focal stiffness and abnormal
postures of his right hand. There was no infection or
vaccination prior to the onset of symptoms. Subsequently,
he developed abnormal postures and involuntary move-
ments in his whole right upper limb described as slow,
strained abduction and elevation of the shoulder and
flexion of the elbow, wrist and fingers. The motor symptoms
gradually progressed and, over a period of approximately
one year, involved both upper limbs, the neck and face,
truncal muscles and the lower limbs. From the age of
twelve years he lost unsupported locomotion. He is now
eighteen years old and wheel-chair dependent with severe
generalized dystonia. He has completed his primary and
secondary education and shows no evidence of cognitive
or psychiatric dysfunction.
Physical examination by the authors at the age of fifteen
revealed severe generalized dystonia with predominantly
tonic features, axial and appendicular rigidity and abnormal
posturing involving the neck, trunk and all four extremities
(Additional file 1). He had facial hypomimia and dystonia,
and oromandibular dystonia with severe dysarthria, but no
dysphagia or dysphonia. Sensory and cerebellar functions
were normal and his cognitive function was unremarkable.
MRI of the brain at the age of nine showed bilateral,
high T2 signal lesions of the posterior putamen, which
were more pronounced on the left side. Subsequent
examinations at the ages of ten, fourteen, seventeen and
eighteen years showed progression of the lesions in a
posteroanterior fashion gradually involving all of the
putamen and extending into the left caudate nucleus
(Figure 1). The putaminal lesions appeared cavitated on
T1 and FLAIR sequences and showed high apparent
diffusion coefficient (ADC) on diffusion weighted imaging
(DWI). The left caudate lesion appeared oedematous with
high T2 signal and heterogeneous water diffusion with low
ADC corresponding to the newest parts of the lesion
(Figure 2). The nucleus accumbens and pallidum were
spared and no other abnormalities were seen in the
brain. There was no contrast enhancement on repeated
examinations.
Whole body positron emission tomography (PET)
imaging with fluor-18-deoxy-glucose (FDG) was performed
at the age of eighteen on a Siemens Biograph 40 PET-CT.
FDG-PET of the brain showed glucose hypermetabolism in
the frontal cortex and hypometabolism in the cerebellum.
There was no tracer uptake in the putamen and reduced
uptake in the left caudate (Figure 3). PET-CT of the torsoshowed no abnormalities and ultrasound of the testes
revealed no signs of teratomas or other neoplasms.
CSF analysis on several occasions showed normal cell
count and mildly elevated protein (0.52-0.53 g/L), but no
oligoclonal bands. Antibodies against the NR1 subunit of
the NMDA receptor were detected using transfected cells
produced by Euroimmun Medizinische Labordiagnostika
AG (D-2356 Lübeck) in the patient’s serum and CSF.
Screening for other autoantibodies to nervous system
antigens was negative including anti-Hu, Ri, Yo, Tr, MAG,
myelin, Ma/Ta, GAD, amphiphysin, AMPA, GABA-b
receptor, LGI1, CASPR2 and glycine receptors.
He had normal metabolic screening in blood, CSF and
urine. Wilson’s and Leigh disease due to mitochondrial
DNA or SURF1 mutations were excluded. He was
thoroughly evaluated for mitochondrial disease including
Figure 3 FDG-PET (left), axial T2 MRI (middle) and
superimposed PET-MRI images of the brain showing frontal
hypermetabolism (A), no detectable uptake in the putamina
and reduced uptake in the left caudate (B) and
hypometabolism in the cerebellum (C).
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DNA analysis with normal findings. Analysis of DYT1,
RRM2B, SUCLA2 and OPA1 genes was normal.
The patient received five intravenous immunoglobulin
(IVIg) infusions (Kiovig 0.4 g/day) followed by two more
infusions a month later and a new screening for anti-
NMDAR antibodies one month later (2 months after
treatment start) was negative in serum and CSF. Three
months after the first IVIg infusion his clinical status and
MRI findings, including lesional ADC, are stable but there
have not been signs of clinical improvement. He receives
regular intramuscular injections of Incobotulinum toxin A
in the upper limbs resulting in moderate improvement in
motor function.
This work has been deemed quality control by our local
ethical committee (Regional Committee for Medical
Research Ethics in Western Norway).
Conclusions
We report a case of generalized dystonia due to BSN
associated with anti-NMDAR antibodies. Unlike the
cases of anti-NMDAR encephalitis, our patient has a
pure, predominantly tonic dystonia with an insidious
onset and slowly progressive course. The selectivity of
the brain lesions is striking. There is involvement ofthe dorsal striatum (putamen and caudate nucleus),
which is predominantly involved in motor function
and sparing of the ventral striatal structures (nucleus
accumbens, olfactory bulb), which are mostly connected
to the limbic system and involved in cognitive and
emotional functions. This localization correlates well
with the clinical features of our patient who had a
pure movement disorder with no signs of psychiatric
or cognitive dysfunction or impaired consciousness.
One patient with isolated hemidystonia and anti-
NMDAR antibodies has been reported [4]. Unlike
our case, that patient had an acute onset and normal
MRI and responded well to treatment. It is however
possible that early treatment in that case prevented
the development of striatal lesions and generalized
dystonia.
The finding of restricted diffusion suggests cytotoxic
edema affecting neurons in the newest parts of the
lesions. The etiology of this damage is unclear, but
may reflect direct antibody-mediated damage and/or
excitotoxicity. Neuronal hyperexcitability is reported
with anti-NMDAR antibodies [9] and the lack of contrast
leakage in the patient’s lesions, suggesting an intact local
blood-brain barrier, and minor CSF findings, would speak
against an aggressive intrathecal inflammation.
Treatment with IVIg decreased the patient’s antibody
titer below detection levels, but has thus far not produced
apparent clinical effects. This is not surprising given the
extensive damage in the patient’s striatum and the short
observation time. On the positive side, his disease has not
shown further progression, but longer follow-up is
required before the treatment response can be confidently
assessed.
While our study is based on only one case, it is highly
unlikely that the anti-NMDAR antibodies in our patient
are an incidental finding. Anti-NMDAR antibodies are
rare and false positive occurrence in both serum and
CSF has not been reported. A pathogenic role for the
antibodies in our patient is also supported by the FDG-
PET findings of frontal hypermetabolism and cerebellar
hypometabolism, which although not specific, are con-
sistent with findings reported in patients with encephal-
itis [10]. As the NMDR antibodies were detected at a
late stage of disease in our patient, it could also be
argued that they represent a secondary phenomenon e.g.
due to chronic neuronal damage leading to peripheral
“leakage” and immune presentation of cerebral antigens.
This however is also unlikely as we found no evidence of
blood-brain barrier dysfunction and detected no other
auto-antibodies to neuronal antigens. Irrespective of
whether the NMDAR antibodies are a primary or
secondary phenomenon, it appears highly likely to us
that they contribute to the neuronal damage in the striatum
of our patient.
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immunity may be an unrecognized cause of dystonia
with BSN. While further cases are needed to elaborate the
mechanisms involved, we feel that our study highlights
the need to thoroughly investigate cases with BSN as early
identification may provide the opportunity for better and
more effective treatment. We suggest, therefore, that
anti-NMDAR antibodies should be included in the work
up of chronic movement disorders with MRI evidence
of striatal necrosis.
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